Packing containers of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024.
Hollie Adams | Reuters
Gross sales of Novo Nordisk‘s blockbuster Wegovy weight reduction drug surged within the second quarter, the corporate mentioned in its newest report, days after slicing its full-year steerage and saying a brand new CEO.
General revenues rose 13% year-on-year at fixed change charges to 76.86 billion Danish kroner ($11.92 billion) within the three months to the tip of June, simply forward of the 76.6 billion Danish kroner forecast.
Gross sales of its blockbuster Wegovy weight problems drug rose 67% over the interval to 19.53 billion Danish kroner, barely under the 20 billion Danish kroner analysts had forecast.
Quarterly web revenue got here in at 26.5 billion Danish kroner, versus 26.6 billion Danish kroner analysts anticipated.
This can be a growing story. Please examine again for updates.
